News Home

Will Ionis Pharmaceuticals Inc (IONS) Beat the Rest of the Stocks in the Healthcare Sector?

Wednesday, March 30, 2022 04:13 PM | InvestorsObserver Analysts

Mentioned in this article

Will Ionis Pharmaceuticals Inc (IONS) Beat the Rest of the Stocks in the Healthcare Sector?

The 30 rating InvestorsObserver gives to Ionis Pharmaceuticals Inc (IONS) stock puts it near the middle of the Healthcare sector. In addition to scoring higher than 61 percent of stocks in the Healthcare sector, IONS’s 30 overall rating means the stock scores better than 30 of all stocks.

Overall Score - 30
IONS has an Overall Score of 30. Find out what this means to you and get the rest of the rankings on IONS!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Ionis Pharmaceuticals Inc Stock Today?

Ionis Pharmaceuticals Inc (IONS) stock is trading at $35.69 as of 4:00 PM on Wednesday, Mar 30, a drop of -$0.79, or -2.17% from the previous closing price of $36.48. The stock has traded between $35.36 and $36.61 so far today. Volume today is below average. So far 450,709 shares have traded compared to average volume of 938,864 shares. Click Here to get the full Stock Report for Ionis Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App